Development and validation of a LC-MS/MS method with electrospray ionization for determination of LASSBio-579 in rat plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 43, Issue 2, 2007, Pages 677-682

  Conrado, D J ^a   Palma, E C ^a   Fraga, C A M ^b   Barreiro, E J ^b   Rates, S M K ^a   Dalla Costa, T ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

LASSBio 579; LC MS MS; Pharmacokinetics; Validation

Indexed keywords

1 [1 (4 CHLORO PHENYL) 1H [1,2,3]TRIAZOL 4 YLMETHYL] 4 PHENYL PIPERAZINE; 1 [1 (4 CHLORO PHENYL) 1H PYRAZOL 4 YLMETHYL] 4 PHENYLPIPERAZINE; AMPHETAMINE; APOMORPHINE; DOPAMINE 2 RECEPTOR; FLUCONAZOLE; LASSBIO 579; LASSBIO 581; NEUROLEPTIC AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CALIBRATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSTRUMENTATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA; PRIORITY JOURNAL; PSYCHOSIS; QUALITY CONTROL; RAT; SCHIZOPHRENIA; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; FLUCONAZOLE; INJECTIONS, INTRAPERITONEAL; LINEAR MODELS; MALE; MOLECULAR STRUCTURE; PIPERAZINES; RATS; RATS, WISTAR; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 33845628660     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2006.07.052     Document Type: Article

References (9)

1. Svensson T.H. Clin. Neurosci. Res. 3 (2003) 34-46
2. Gaszner P., and Makkos Z. Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 28 (2004) 465-469
3. Menegatti R., Cunha A.C., Ferreira V.F., Perreira E.F.R., El-Nebawi A., Eldefrawi A.T., Albuquerque E.X., Neves G., Rates S.M.K., Fraga C.A.M., and Barreiro E.J. Bioorg. Med. Chem. 11 (2003) 4807-4813
4. Neves G., Fenner R., Heckler A.P., Viana A.F., Tasso L., Menegatti R., Fraga C.A.M., Barreiro E.J., Dalla Costa T., and Rates S.M.K. Braz. J. Med. Biol. Res. 36 (2003) 625-629
5. Tasso L., Neves G., Menegatti R., Fraga C.A.M., Barreiro E.J., Eifler-Lima V.L., Rates S.M.K., and Dalla Costa T. J. Pharm. Biomed. Anal. 33 (2003) 1127-1133
6. Tasso L., Neves G., Menegatti R., Fraga C.A.M., Barreiro E.J., Eifler-Lima V.L., Rates S.M.K., and Dalla Costa T. Eur. J. Pharm. Sci. 26 (2005) 194-202
7. Santos L.S., Padilha M.C., Aquino Neto F.R., Pereira A.S., Menegatti R., Fraga C.A.M., Barreiro E.J., and Eberli M.N. J. Mass Spectrom. 40 (2005) 815-820
8. Dongre V.G., Karmusea P.P., Ghugre P.D., Salunke S.M., Panda N., and Kumarb A. J. Pharm. Biomed. Anal. 42 (2006) 334-340
9. FDA. Guidance for Industry. Bioanalytical Method Validation, May 2001. (http://www.fda.gov/cder/guidance/index.htm).